Pulmonary Pharmacokinetics of Oseltamivir Carboxylate in Rats after Nebulization or Intravenous Administration of Its Prodrug, Oseltamivir Phosphate

Antimicrob Agents Chemother. 2019 May 24;63(6):e00074-19. doi: 10.1128/AAC.00074-19. Print 2019 Jun.

Abstract

The aim of this study was to investigate the pharmacokinetics of oseltamivir phosphate, a prodrug, and its active moiety in plasma and lung after its nebulization and intravenous administration in rats. Only 2% of prodrug was converted into active moiety presystematically, attesting to a low advantage of oseltamivir phosphate nebulization, suggesting that oseltamivir phosphate nebulization is not a good option to obtain a high exposure of the active moiety at the infection site within lung.

Keywords: lung; nebulization; oseltamivir; pharmacokinetics; prodrug.

MeSH terms

  • Administration, Intravenous
  • Animals
  • Male
  • Oseltamivir / administration & dosage
  • Oseltamivir / analogs & derivatives*
  • Oseltamivir / blood
  • Oseltamivir / pharmacokinetics*
  • Oseltamivir / pharmacology
  • Phosphates
  • Prodrugs / administration & dosage
  • Prodrugs / pharmacokinetics*
  • Rats
  • Rats, Sprague-Dawley

Substances

  • Phosphates
  • Prodrugs
  • Oseltamivir
  • oseltamivir carboxylate